Strategic Partners

Strategic partnerships are an important part of our business strategy to create value for investors and patients.

In December 2019, Catalyst Biosciences and Biogen entered into a global license and collaboration agreement for the development and commercialization of pegylated CB 2782 (CB 2782-PEG) for the potential treatment of geographic atrophy (GA) associated dry age-related macular degeneration (dry AMD).

Under the terms of the agreement, Biogen has an exclusive worldwide license to develop and commercialize CB 2782-PEG and Catalyst’s other anti-C3 proteases for the potential treatment of dry  AMD. Catalyst is performing pre-clinical and manufacturing activities and Biogen is solely responsible for funding the pre-clinical and manufacturing activities and performing Investigational New Drug (IND)-enabling activities, worldwide clinical development, and commercialization.